Pinkerton 2017.

Methods	RCT, multicentre, USA and Canada
Participants	Inclusion criteria Healthy postmenopausal women Those seeking treatment for menopausal symptoms Those with moderate/severe vasomotor symptoms Postmenopausal women aged 40‐75 years
Interventions	Intervention: conjugated estrogen (CE)/bazedoxifene (BZA) (CE 0.45 or 0.625 mg with BZA 10, 20, or 40 mg), raloxifene 60 mg Control: placebo
Outcomes	Sexual activity and health‐related QoL
Notes	Pending other possible secondary results derived from the study